A Phase 1 Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Glioblastoma
- Sponsor
- Immatics Biotechnologies GmbH
- Enrollment
- 6
- Locations
- 1
- Primary Endpoint
- Safety and tolerability of IMA950 administered with granulocyte macrophage colony stimulating factor (GM-CSF) and topical imiquimod together following a single low-dose application of cyclophosphamide.
- Status
- Terminated
- Last Updated
- 11 years ago
Overview
Brief Summary
BACKGROUND: Active immunotherapy of cancer is based on the premise that the vaccine raises a cytotoxic immune response to tumor-associated antigens, thereby destroying malignant cells without harming normal cells.
IMA950 is a therapeutic multi-peptide vaccine containing 11 tumor-associated peptides (TUMAPs) found in a majority of glioblastomas, and is designed to activate TUMAP-specific T cells. The use of 11 TUMAPs increases the likelihood of a multi-clonal, highly specific T-cell response against tumor cells leading to decreased likelihood of immune evasion of the tumor by down-regulation of target antigens.
PURPOSE: The primary objective of this study is to determine the safety and tolerability of IMA950 when given with cyclophosphamide, granulocyte macrophage-colony stimulating factor (GM-CSF) and imiquimod in patients with glioblastoma and to determine if IMA950 shows sufficient immunogenicity in these patients.
ELIGIBILITY: Patients with histologically proven GBMs who have completed radiotherapy, and have stable disease following at least 4 cycles of adjuvant temozolomide.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Safety and tolerability of IMA950 administered with granulocyte macrophage colony stimulating factor (GM-CSF) and topical imiquimod together following a single low-dose application of cyclophosphamide.
Time Frame: Continuously for up to 1 year plus follow-up
Number of AEs and percentage of patients with AEs (listed per grade and MedDRA preferred terms) will be reported.
Immunogenicity of IMA950
Time Frame: 6 time points (blood drawings) during the first 3 months (pre- and post-vaccination)
Vaccine-induced immune responses to peptides contained in IMA950 will be measured by multimer assay using peripheral blood. Percentage of immune responders (patients with at least one vaccine-induced immune response to IMA950 peptides) and percentage of multi-TUMAP responders (patients with vaccine-induced immune responses to ≥2 peptides in IMA950) will be reported.
Secondary Outcomes
- Immune status parameters(6 time points (blood drawings) during the first 3 months on study (pre-vaccination and during vaccination period))
- Biomarker assessment and correlation to clinical and immunological response(Analysis time points are before the first vaccination and 15 weeks thereafter)
- Clinical anti-tumor activity (response rate, 6-month progression-free survival)(Will be followed for 1 year (until end of study visit), overall survival will also be followed thereafter)
- Influence of corticosteroids on immunogenicity of IMA950(6 time points (blood drawings) during the first 3 months (pre- and post-vaccination))
- Health-related quality of life(Monthly for 1 year)